Results 221 to 230 of about 6,799 (258)

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Fecal Microbiome and Bile Acid Profiles Differ in Preterm Infants with Parenteral Nutrition-associated Cholestasis. [PDF]

open access: yesJ Clin Transl Hepatol
Wagner ES   +6 more
europepmc   +1 more source

Biomimetic MCC950‐loaded cerium‐layered double hydroxide nanoparticles for targeted treatment of Type 1 diabetes in streptozotocin‐induced mice

open access: yesBritish Journal of Pharmacology, EarlyView.
The CLMBM nanoparticle (NP) system demonstrates strong and targeted anti‐ROS, antiapoptotic and anti‐inflammatory properties within the pancreas, thereby inhibiting the onset and progression of type 1 diabetes. Background and Purpose The destruction of β‐cells in type 1 diabetes is driven by signalling cascades that ultimately lead to cell apoptosis ...
Huiwen Pang   +9 more
wiley   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

open access: yesCancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka   +5 more
wiley   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

open access: yesCancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou   +15 more
wiley   +1 more source

A preliminary study on NLRP3 activation and the interventional effects of MCC950 in Con A-induced EAH mice. [PDF]

open access: yesTransl Pediatr
Ma D   +10 more
europepmc   +1 more source

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy